StockTipsArenaBeta

BUY Piramal Pharma Limited — Goldman Sachs

BUYPiramal Pharma Limited

byGoldman SachsHorizon: NA (inferred 1 year)24 Sept 2026via Zee Business (Live)

Entry₹210.65Inferred
Target₹250
Total upside +18.68%
Stop lossNot given
CMP₹210.55Just now
Active-0.05%+18.74%upside left 12 mo left
Follow Goldman Sachs for new calls(100% target hit, 16 closed calls)Get alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 5 other Long-term calls on PPLPHARMASee 111 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 24 Sept, 10:42 am IST
21 supporting9 neutral7 opposing
Supports the BUY call (21)

Piramal Pharma earns ‘Leader’ ESG rating from independent assessor

NewsGoogle News·18 Sept · 5d ago

(opens in new tab)

Piramal Pharma CDMO Strategy Helps Clients Navigate US Tariff Risks

NewsGoogle News·5 Sept · 3w ago

(opens in new tab)

Piramal Pharma: अमेरिकी टैरिफ के खतरे के बीच कंपनी की नई स्ट्रैटेजी, मुनाफे में दमदार उछाल

NewsGoogle News·5 Sept · 3w ago

(opens in new tab)

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

NewsGoogle News·26 Aug · 4w ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·26 Aug · 4w ago

Neutral / worth noting (9)

Piramal Pharma gets 7 observations from US FDA at Morpeth UK facility

NewsCnbc-Tv18·14 Sept · 1w ago

(opens in new tab)

US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US

NewsGoogle News·27 Aug · 4w ago

(opens in new tab)

US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US

NewsGoogle News·27 Aug · 4w ago

(opens in new tab)
Weighs against the BUY call (7)

Long-term trend bearish — 200-day average falling over the past quarter

Technicals · trend·23 Sept · yesterday

Piramal Pharma shares fall 3% after USFDA issues 7 observations at UK facility

NewsCnbc-Tv18·15 Sept · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.